DDInter40 DDInter922
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.[A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies.[A214280, A214295] On January 16, 2024, Iinebilizumab also received Health Canada approval for the same indication.
Alefacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bleomycin
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibritumomab tiuxetan
Alefacept {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ibritumomab tiuxetan
Alefacept may lead to a major life threatening interaction when taken with Upadacitinib